多参数MRI与18F-PSMA-1007 PET/CT检测临床显著前列腺癌
前瞻性研究纳入75例PSA升高并接受前列腺mpMRI的受试者,于mpMRI后30天内、活检前行18F-PSMA-1007 PET/CT。以组织学为参考标准、ISUP≥2为csPCa,mpMRI与PET/CT的每受试者敏感度分别为95%和91%,特异度分别为45%和62%;PET/CT正确鉴别26个PI-RADS 3病灶中的17个(65%),排除csPCa的阴性预测值为93%。
要点
- 18F-PSMA-1007 PET/CT检测csPCa的每受试者敏感度91%、特异度62%,mpMRI分别为95%、45%。
- 对PI-RADS 3病灶,PET/CT正确鉴别17/26个(65%),排除csPCa的阴性预测值93%、阳性预测值27%。
- PET/CT额外发现1个显著和1个不显著PCa病灶(PI-RADS 1或2),另有2例ISUP 2肿瘤无PSMA摄取而被PET/CT漏诊。
核心结论
- 18F-PSMA-1007 PET/CT检测csPCa显示良好敏感度和中等特异度,并在93%的PI-RADS 3病灶受试者中排除csPCa。
研究设计与样本
- 前瞻性研究,2020年9月至2022年2月纳入PSA升高并转诊行前列腺mpMRI的受试者75例(中位年龄67岁,范围52-77岁),PI-RADS 1或2、PI-RADS 3、PI-RADS 4或5三组各25例。
关键影像表现/征象
- 共识别102个病灶,其中80个为PI-RADS 3或以上和/或LOS 3或以上并接受靶向活检。
- 18F-PSMA-1007 PET/CT额外发现1个显著和1个不显著PCa病灶(PI-RADS 1或2),否则不会被发现。
- 2例受试者ISUP 2肿瘤无PSMA摄取,被PET/CT漏诊。
诊断标准与关键数值
- 以组织学检查为参考标准,ISUP分级2或以上定义为csPCa。
- mpMRI每受试者检测csPCa敏感度95%、特异度45%;18F-PSMA-1007 PET/CT敏感度91%、特异度62%。
- 18F-PSMA-1007 PET/CT正确鉴别26个PI-RADS 3病灶中的17个(65%),排除csPCa的阴性预测值93%、检出csPCa的阳性预测值27%。
临床应用与阅片要点
- mpMRI PI-RADS 3或以上和/或18F-PSMA-1007 PET/CT LOS 3或以上的病灶接受靶向活检。
- PI-RADS 2或以下且LOS 2或以下的病灶视为不怀疑,通过PSA检测进行1年随访监测。
局限性
- 2例受试者ISUP 2肿瘤无PSMA摄取而被PET/CT漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Multiparametric MRI (mpMRI) is effective for detecting prostate cancer (PCa); however, there is a high rate of equivocal Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions and false-positive findings. Purpose To investigate whether fluorine 18 (18F) prostate-specific membrane antigen (PSMA) 1007 PET/CT after mpMRI can help detect localized clinically significant PCa (csPCa), particularly for equivocal PI-RADS 3 lesions. Materials and Methods This prospective study included participants with elevated prostate-specific antigen (PSA) levels referred for prostate mpMRI between September 2020 and February 2022. 18F-PSMA-1007 PET/CT was performed within 30 days of mpMRI and before biopsy. PI-RADS category and level of suspicion (LOS) were assessed. PI-RADS 3 or higher lesions at mpMRI and/or LOS 3 or higher lesions at 18F-PSMA-1007 PET/CT underwent targeted biopsies. PI-RADS 2 or lower and LOS 2 or lower lesions were considered nonsuspicious and were monitored during a 1-year follow-up by means of PSA testing. Diagnostic accuracy was assessed, with histologic examination serving as the reference standard. International Society of Urological Pathology (ISUP) grade 2 or higher was considered csPCa. Results Seventy-five participants (median age, 67 years [range, 52-77 years]) were assessed, with PI-RADS 1 or 2, PI-RADS 3, and PI-RADS 4 or 5 groups each including 25 participants. A total of 102 lesions were identified, of which 80 were PI-RADS 3 or higher and/or LOS 3 or higher and therefore underwent targeted biopsy. The per-participant sensitivity for the detection of csPCa was 95% and 91% for mpMRI and 18F-PSMA-1007 PET/CT, respectively, with respective specificities of 45% and 62%. 18F-PSMA-1007 PET/CT was used to correctly differentiate 17 of 26 PI-RADS 3 lesions (65%), with a negative and positive predictive value of 93% and 27%, respectively, for ruling out or detecting csPCa. One additional significant and one insignificant PCa lesion (PI-RADS 1 or 2) were found at 18F-PSMA-1007 PET/CT that otherwise would have remained undetected. Two participants had ISUP 2 tumors without PSMA uptake that were missed at PET/CT. Conclusion 18F-PSMA-1007 PET/CT showed good sensitivity and moderate specificity for the detection of csPCa and ruled this out in 93% of participants with PI-RADS 3 lesions. Clinical trial registration no. NCT04487847 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Turkbey in this issue.
引用
- Privé BM, Israël B, Janssen MJR, et al. Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer. Radiology. 2024. PMID: 38771185. doi:10.1148/radiol.231879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。